Active-ingredient Dossier
Aripiprazole
Active-ingredient Dossier for Aripiprazole (atypical antipsychotic). Australian brands, products, PBS listings, PBAC outcomes — compiled by arcimedes.
- Brand: ABILIFY
- Brand: ABILIFY
- Brand: ARIPIPRAZOLE SANDOZ
- Brand: APO-ARIPIPRAZOLE
- Brand: ARIPENA
- Brand: ARIPIPRAZOLE GH
- Therapeutic area: Psychiatry
What is
Aripiprazole Aripiprazole is an atypical antipsychotic.
Australian brands containing
Aripiprazole — ABILIFY — ARIPIPRAZOLE SANDOZ — ABYRAZ — APO-ARIPIPRAZOLE — ARIPIPRAZOLE GH — ARIPIPRAZOLE-WGR — ARIZOLE — AURO-ARIPIPRAZOLE — APRAZOLE
Therapeutic areas
Aripiprazole is registered in neurology, with 14 brands containing this ingredient on the ARTG.
Sponsor landscape
The ingredient is marketed by ten sponsors: Arrotex Pharmaceuticals, Accord Healthcare, Otsuka Australia Pharmaceutical, Lundbeck, Alphapharm, and Generic Health, among others.
PBS and regulatory activity
Three brands containing aripiprazole have PBS-listed items. The latest PBS schedule date is 1 May 2026. In the 2020–21 financial year, government PBS expenditure on aripiprazole was approximately $63.1 million across 388,414 prescriptions. The latest PBAC outcome was recorded on 1 July 2025. The latest AusPAR was published on 22 July 2014.